Table 5

 Most common (⩾5%) treatment related adverse events

Adverse eventPlacebo (n = 95)Exisulind 200 mg (n = 91)Exisulind 400 mg (n = 95)p Value*
AST, aspartate aminotransferase; ALT, alanine aminotransferase.
*Exisulind 400 mg versus placebo.
Abdominal pain3 (3.2%)3 (3. 3%)14 (14.7%)0.005
ALT increased1 (1.1%)1 (1.1%)8 (8.4%)0.017
AST increased1 (1.1%)1 (1.1%)8 (8.4%)0.017
Alkaline phosphatase2 (2.1%)2 (2.2%)7 (7.4%)0.085
Dyspepsia4 (4.2%)4 (4.4%)5 (5.3%)0.5
Diarrhoea3 (3.2%)3 (3.3%)5 (5.3%)0.36